Does insurance cover Mounjaro in New York?

If you’re considering weight-loss medications like Wegovy, Ozempic, or Mounjaro, one of your first questions is probably: Will my insurance cover it? The short answer is—maybe. But navigating the coverage landscape for GLP-1 medications can feel like trying to solve a puzzle with missing pieces. Whether your insurance pays, how much you’ll owe, and what hoops you’ll need to jump through depend heavily on your type of insurance, your state, and whether your doctor prescribes the drug for diabetes or weight loss.

In this guide, we’ll break down everything you need to know about insurance coverage for these game-changing medications in 2025—including what to expect from commercial insurance, Medicare, and Medicaid, common reasons for denials, how to appeal, and your best options if you have to pay out of pocket.

Understanding the Three Major GLP-1 Medications

Before we dive into insurance specifics, let’s quickly clarify what we’re talking about:

• Wegovy (semaglutide): FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition. It’s the same active ingredient as Ozempic but formulated and approved for weight loss.

• Ozempic (semaglutide): FDA-approved for treating Type 2 diabetes. While it’s the same drug as Wegovy, insurers only cover Ozempic when prescribed for diabetes—not for off-label weight loss.

• Mounjaro (tirzepatide): FDA-approved for Type 2 diabetes. A similar version called Zepbound is approved for obesity, but like Ozempic, insurers typically won’t cover Mounjaro for weight loss alone.

The key takeaway? Insurance usually covers these medications for their FDA-approved uses—diabetes for Ozempic and Mounjaro, weight loss for Wegovy—but even then, there are significant barriers.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Does Commercial Insurance Cover These Medications?

Wegovy for Weight Loss: Limited and Restrictive

Most employer-sponsored health plans and marketplace plans treat anti-obesity medications as optional benefits, not essential health benefits. This means your employer or insurer can choose whether to cover them at all. According to recent data, fewer than half of large employer plans covered GLP-1 weight-loss drugs as of 2024, and many that do impose strict criteria.

If your plan does cover Wegovy, expect to navigate:

• Prior authorization (PA): Nearly universal. You’ll need documentation showing a BMI of 30 or higher (or 27+ with conditions like high blood pressure or sleep apnea), proof of at least six months of supervised diet and exercise attempts, and sometimes evidence that you tried other weight-loss medications first.

• Step therapy: Some insurers require you to try older, cheaper weight-loss drugs (like phentermine or orlistat) before approving Wegovy.

• Tier placement: Wegovy typically lands on Tier 3 (non-preferred brand) or Tier 4 (specialty), meaning higher copays or coinsurance—often $100–$500+ per month even with coverage.

• Ongoing requirements: Many plans require periodic check-ins (every 3–6 months) to confirm you’re losing weight (usually at least 5% of body weight). If you don’t meet these benchmarks, coverage can be discontinued.

Common exclusions: Some plans explicitly exclude ‘drugs for weight control’ in their formularies. If that’s the case, no amount of medical necessity will get Wegovy covered unless your employer renegotiates the plan.

Ozempic and Mounjaro for Diabetes: Generally Covered

The picture is brighter if you have Type 2 diabetes. Ozempic and Mounjaro are widely covered under pharmacy benefits because diabetes treatment is considered essential.

That said:

• Prior authorization is still common to confirm your diabetes diagnosis and ensure you’ve tried first-line treatments like metformin.
• Step therapy may require trying other diabetes medications or even another GLP-1 before Mounjaro (which is newer and more expensive).
• Off-label denials: If you don’t have diabetes and your doctor prescribes Ozempic or Mounjaro for weight loss, expect a denial. Insurers flag these requests and will only approve them for FDA-approved indications.

Bottom line for commercial insurance: Diabetes use? Likely covered with some paperwork. Weight-loss use? Possible but difficult, and many plans simply don’t cover it.

What About Medicare?

Medicare Part D and Weight Loss: Still a No-Go

Here’s the frustrating reality: Traditional Medicare Part D does not cover medications prescribed solely for weight loss. This is due to a federal law that excludes ‘drugs used for anorexia, weight loss, or weight gain’ from Medicare coverage.

There is one important exception: In March 2024, CMS approved coverage of Wegovy for Medicare beneficiaries with cardiovascular disease who are obese, because it’s approved to reduce cardiovascular risk—not just for weight loss. So if you have heart disease and obesity, Wegovy may be covered under Part D.

Medicare and Diabetes Medications

Ozempic and Mounjaro are covered under Part D for Type 2 diabetes, just like commercial plans. Expect similar prior authorization requirements and formulary tiers (usually Tier 3).

Medicare Advantage plans have started offering limited obesity drug coverage in 2025, but it varies widely by plan and region. Check your plan’s formulary if you’re in an MA plan.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss drugs is highly state-dependent. As of late 2024, only about 13 states cover medications like Wegovy through Medicaid—and that number is shrinking due to budget pressures.

States That Cover (or Covered) Wegovy

Here’s what’s happening in key states:

California (Medi-Cal):
Covered Wegovy with strict prior authorization in 2025, requiring BMI ≥30 (or ≥27 with comorbidities) and documented six-month diet/exercise attempts. However, coverage ends January 1, 2026, due to state budget cuts. After that date, Wegovy will no longer be covered for adults (though pediatric patients may still access it under EPSDT—Early and Periodic Screening, Diagnostic, and Treatment).

Pennsylvania:
Pennsylvania Medicaid began covering Wegovy in 2023 with stringent criteria: BMI ≥30 or ≥27 with weight-related conditions, prior lifestyle modification, and if the patient has diabetes, they must try a diabetes-focused GLP-1 first. But like California, Pennsylvania is ending this coverage in January 2026 to control costs.

New York:
New York Medicaid continues to cover Wegovy and similar anti-obesity medications under its NYRx formulary, with prior authorization required. Patients must meet FDA labeling criteria (BMI thresholds, comorbidities, documented lifestyle attempts). Quantity limits apply (typically four pens per 28 days).

Texas:
Texas Medicaid does not cover any anti-obesity medications for adults. The state invokes the federal optional exclusion for weight-loss drugs. Patients under 21 may request exceptions via EPSDT, but adult coverage is prohibited.

Florida:
Florida Medicaid similarly excludes weight-loss drugs entirely. Only diabetes medications like Ozempic (for Type 2 diabetes) are covered.

Illinois:
Illinois Medicaid does not cover Wegovy or obesity drugs as of 2025. While the state expanded coverage for state employees in 2023, Medicaid enrollees remain without access.

Medicaid Bottom Line

Even in states that cover GLP-1 weight-loss medications, prior authorization is mandatory and criteria are strict. Documentation of high BMI, comorbid conditions, supervised weight-loss attempts (often six months minimum), and periodic progress checks are standard. Given the high cost (Wegovy costs states ~$1,350 per patient per month at list price), many states are pulling back coverage entirely.

If you’re on Medicaid, check your state’s formulary and be prepared for significant barriers—or outright denial in most states.

Common Reasons for Denial (And How to Appeal)

Even if your plan technically covers GLP-1 medications, getting approved isn’t automatic. Here are the most common reasons for denial:

1. Not Meeting Medical Necessity Criteria

Insurers require documented evidence of a qualifying BMI (usually ≥30 or ≥27 with comorbidities). If your medical records don’t clearly show this—or if comorbid conditions aren’t documented—expect a denial.

2. Insufficient Documentation of Prior Attempts

Most plans require proof that you’ve tried lifestyle interventions (diet, exercise, behavioral therapy) for at least six months under medical supervision. If your doctor can’t provide detailed records, your claim may be rejected.

3. Step Therapy Failure

Some insurers want you to try older, cheaper weight-loss medications first. If you haven’t, they’ll deny coverage for Wegovy and ask you to start with something like phentermine or orlistat.

4. Off-Label Use

Prescribing Ozempic or Mounjaro for weight loss when you don’t have diabetes? That’s a near-guaranteed denial. Insurers tightly enforce FDA indications.

5. Plan Exclusions

If your policy explicitly excludes ‘weight control drugs,’ no appeal will succeed unless your employer amends the plan.

How to Appeal a Denial

If your initial request is denied, don’t give up. Here’s how to appeal effectively:

Gather comprehensive documentation:

• Detailed medical records showing BMI measurements over time
• Documentation of weight-related health conditions (hypertension, prediabetes, sleep apnea, etc.)
• Records of supervised diet and exercise programs
• A letter of medical necessity from your doctor explaining why you specifically need this medication

Submit a formal appeal:
Most insurers have a two-step appeals process. Start with an internal appeal (often decided within 5–15 business days for urgent requests, up to 30 days for standard appeals).

Be persistent:
If the internal appeal fails, you can request an external review through your state’s insurance department. Studies suggest that a significant portion of denials are overturned when proper documentation is provided—especially for patients with BMI ≥35 and documented health risks.

Work with your doctor:
Your physician’s advocacy matters. A well-written letter citing clinical guidelines, your specific medical history, and why alternatives have failed can tip the scales.

Timeline expectations: Initial prior authorization decisions typically come within 3–7 business days. Appeals can take 2–4 weeks, depending on urgency and your state’s regulations.

Can You Use Telehealth for Weight Loss Medications?

Yes—and in many cases, telehealth makes access easier. Since the pandemic, telehealth coverage has expanded dramatically. Over 40 states now have parity laws requiring private insurers to cover virtual visits the same as in-person care.

What this means for you:

• If your insurance covers obesity treatment or nutritional counseling, it will likely cover those services via telemedicine.
• You can consult with a provider remotely to get a prescription for Wegovy, Ozempic, or Mounjaro (assuming you meet medical criteria).
• Many insurers now contract with telehealth platforms or allow your primary care provider to conduct virtual weight-management visits.

Important considerations:

• Use in-network providers: Make sure your telehealth platform or provider is in your insurance network to avoid out-of-network charges.
• Video vs. phone: Some insurers require live video consultations (not just phone calls or messaging) for full coverage.
• Prescription coverage is separate: Even if the telehealth visit is covered, you’ll still face the same prior authorization hurdles for the medication itself.

Platforms like Klarity Health offer accessible telehealth consultations for weight management. While the visit itself may be cash-pay depending on your insurance, Klarity’s providers can help you navigate the prior authorization process, provide the necessary documentation, and connect you with transparent pricing options if you’re paying out of pocket. With provider availability across multiple states and acceptance of both insurance and cash payments, Klarity makes it easier to get the care you need—whether you’re working within insurance constraints or exploring self-pay routes.

What If Insurance Won’t Cover It? Your Self-Pay Options

If insurance says no, you’re not out of options. Recent developments have made these medications more affordable for self-paying patients.

Manufacturer Savings Programs

Novo Nordisk (Wegovy and Ozempic):

• Savings Card: If you have commercial insurance but high copays, Novo’s card can reduce your cost to as low as $0 per month (typically covers up to $225 per prescription). Cannot be used with government insurance (Medicare, Medicaid).
• Cash-Pay Program: As of November 2025, Novo’s self-pay price through the NovoCare program is $349 per month for Wegovy or Ozempic (down from $499). This is available at most retail pharmacies.
• Patient Assistance Program: Uninsured or low-income patients who meet financial criteria may receive Wegovy at no cost through Novo’s PAP.

Eli Lilly (Mounjaro and Zepbound):

• Savings Card: For patients with commercial insurance and a Type 2 diabetes diagnosis, the card can reduce Mounjaro to $25 per month.
• LillyDirect Cash-Pay: Lilly now offers single-dose Zepbound vials at $299–$449 depending on dose (down from $499), available through their direct-to-consumer platform.
• Patient Assistance: Lilly’s PAP provides free medication to qualifying uninsured individuals.

GoodRx Partnership Pricing

In November 2025, GoodRx announced a groundbreaking partnership with Novo Nordisk:

• Introductory pricing: $199 per month for the first two fills of Wegovy or Ozempic
• Ongoing pricing: ~$349 per month after the intro period
• Availability: Works at nearly all U.S. pharmacies

This represents a 60–70% discount off list prices and is available to anyone paying cash, regardless of insurance status.

Cost Comparison Table

What About Compounded Versions?

Some telehealth clinics and wellness centers offer compounded semaglutide or tirzepatide at lower prices (often $200–$400/month). Proceed with caution. These formulations are not FDA-approved, may have quality and safety concerns, and insurers won’t cover them. Stick with FDA-approved medications when possible.

Other Lower-Cost Alternatives

If GLP-1s are out of reach financially, consider:

• Phentermine: ~$30–$50/month (generic available, insurance often covers)
• Orlistat (Alli/Xenical): ~$50–$100/month over-the-counter
• Combination medications (Qsymia, Contrave): ~$100–$200/month, some insurance coverage

These are less effective than GLP-1s for most patients but may be affordable bridges while you work on insurance approval or save up.

Making the Most of Your Coverage: Practical Tips

Whether you’re working with insurance or paying cash, here’s how to maximize your chances of access:

1. Document everything:
Keep detailed records of your weight, BMI measurements, comorbid conditions, and every diet or exercise program you’ve tried. This is ammunition for prior authorization.

2. Work closely with your provider:
A knowledgeable doctor who understands insurance requirements can craft a strong letter of medical necessity and guide you through the PA process.

3. Check your formulary:
Before your appointment, call your insurer or check their online formulary to see if Wegovy is covered and what tier it’s on. Know the PA requirements upfront.

4. Consider telehealth:
Virtual consultations can be more convenient, often cost less, and providers experienced in weight management (like those at Klarity Health) know how to navigate insurance roadblocks. Klarity offers transparent pricing, accepts both insurance and cash payments, and has providers available in multiple states—making it easier to get started quickly.

5. Plan for appeals:
If you’re denied, don’t accept it as final. About 40–50% of denials for medically appropriate requests are overturned on appeal when proper documentation is provided.

6. Explore manufacturer programs early:
Don’t wait until you’re approved to investigate savings cards and PAPs. These programs can dramatically reduce costs while you’re navigating insurance.

7. Compare pharmacy prices:
Even with insurance, copays can vary by pharmacy. Use GoodRx or similar tools to find the lowest cost in your area.

8. Ask about quantity limits:
Some plans limit how many pens or doses you can get per month. Make sure your prescription aligns with these limits to avoid partial fills.

The Bottom Line: Coverage Is Improving, But Barriers Remain

In 2025, insurance coverage for GLP-1 weight-loss medications is a mixed bag. If you have Type 2 diabetes, getting Ozempic or Mounjaro covered is usually straightforward (though not always cheap). For obesity treatment with Wegovy, you’ll face significant hurdles with commercial insurance—and in many cases, outright exclusions.

Medicare still doesn’t cover weight-loss drugs broadly (except in narrow cardiovascular cases), and Medicaid coverage is rapidly shrinking as cash-strapped states pull back.

But there’s good news: Manufacturer price reductions, innovative savings programs like GoodRx’s partnership with Novo, and expanded telehealth access are making these life-changing medications more reachable than ever—even if you have to pay out of pocket.

If you’re considering a GLP-1 medication, start by checking your insurance coverage and prior authorization requirements. Work with a knowledgeable provider who can help you navigate the process, document your medical necessity, and appeal denials if needed. And if insurance won’t pay, explore the new cash-pay options—you may be surprised at how much more affordable they’ve become.

Ready to explore your weight-loss options? Klarity Health offers convenient telehealth consultations with experienced providers who can evaluate your eligibility for GLP-1 medications, help you understand your insurance coverage, and provide transparent pricing if you’re paying cash. With flexible scheduling, nationwide provider availability, and support for both insured and self-pay patients, Klarity makes it easier to take the next step in your weight-loss journey.

Frequently Asked Questions

Q: Will my insurance cover Wegovy if I meet the BMI requirements?
A: Not necessarily. Even if you meet medical criteria, your plan may exclude weight-loss drugs entirely. Check your formulary and be prepared for prior authorization if coverage exists.

Q: Can I use a manufacturer savings card with Medicare?
A: No. Federal law prohibits using manufacturer coupons or copay cards with Medicare or Medicaid. You’d need to explore patient assistance programs instead.

Q: How long does prior authorization take?
A: Typically 3–7 business days for standard requests, sometimes faster for urgent cases. Appeals can take 2–4 weeks.

Q: Is it worth appealing a denial?
A: Absolutely, especially if you meet medical criteria and have good documentation. Many denials are overturned on appeal.

Q: Can I get Ozempic for weight loss if I don’t have diabetes?
A: Insurers will deny coverage for off-label use. You’d need to pay cash or get Wegovy prescribed instead (if covered).

Q: Are compounded semaglutide products safe?
A: The FDA has raised concerns about quality and safety. Compounded products aren’t FDA-approved and should be used with caution. Always prioritize FDA-approved medications when possible.

Citations and Sources

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

1. Aetna Clinical Policy Bulletin – Weight Loss (BMI ≥35) GIP-GLP-1/GLP-1 Agonists PA with Limit (May 2024). Available at: www.aetna.com

2. SingleCare – Cigna Prior Authorization for Weight Loss: GLP-1 Drugs (April 2024). Available at: www.singlecare.com

3. Amwins Connect – Kaiser Permanente Coverage Changes for GLP-1 Drugs and Anti-Obesity Medications in 2025 (January 2025). Available at: www.amwinsconnect.com

4. Texas Children’s Health Plan – Provider Alert: Non-Formulary Requests for Obesity Control Drugs (March 2023). Available at: www.texaschildrenshealthplan.org

5. Pennsylvania Health Law Project – Pennsylvania Medicaid Covers Newer Weight Loss Drugs (August 2024). Available at: www.phlp.org

All formulary information, Medicaid coverage details, pricing data, and policy updates have been verified as current as of December 17, 2025. Insurance coverage and medication costs can change frequently—always verify your specific plan’s formulary and contact your insurer or pharmacy for the most up-to-date information before making treatment decisions.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499